article thumbnail

FTC, in unusual move, leads Sanofi to terminate a drug research deal

BioPharma Drive: Drug Pricing

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

article thumbnail

Why Proactive AME Studies are Critical to Accelerating Your Approval Journey

Conversations in Drug Development Trends

The on-site cGMP Phase 1 pharmacy must have radiolabel drug preparation experience A clinical pharmacology unit (CPU) must be licensed and experienced in handling radioactive investigational drugs in order to complete your AME study.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Cost of Knowledge: Evaluating Open vs. Paid Data for Pharma

DrugBank

These data sources are known for being highly referenced and usable for specific research activities; further yet, a number of recognizable open sources, along with their identifiers, are considered industry standard resources. Paid Knowledge Bases Paying for access or licensing a knowledge base can be a difficult decision to make.

article thumbnail

Deliberate Dysentery

Codon

We wouldn't do a challenge trial for Ebola, because the disease is extremely severe, and there are currently no licensed treatments or vaccines. There have been deaths in phase 1 medical and drug research among healthy participants. You can do a challenge trial with deadly diseases, but you need a “rescue therapy.”

Vaccine 118
article thumbnail

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and Institute of Microbiology, Chinese Academy of Science (IMCAS). However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization.

article thumbnail

Using clinical genomics and AI in drug development to elevate success

Drug Target Review

New era in drug research: data access and NGS The 1990s and 2000s marked a turning point in the drug development landscape, facilitated by a combination of cultural and technological factors that enabled regulatory changes, technological innovations and methodological advances.